Home Interviews BioStock Investor Pitch: Prolevi Bio

BioStock Investor Pitch: Prolevi Bio

Prolevi Bios vd Sahil Gupta på Medicon Village

BioStock Investor Pitch: Prolevi Bio

27 January, 2023

Privately-owned Prolevi Bio’s goal is to improve the treatment of hypothyroidism, a common condition involving a lack of thyroid hormone. The company has developed a method that releases medicine based on the patient’s circadian rhythm. According to Prolevi Bio, this should improve the effect of the drug, something that CEO Sahil Gupta explains more about in a company presentation in BioStock’s studio.

Watch Prolevi Bio’s CEO Sahil Gupta present the company below.

YouTube video

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev